Otros idiomas Pacira BioSciences, Inc.

Acciones

PCRX

US6951271005

Mercado cerrado - Nasdaq Otros sitios de cotización 22:00:06 16/05/2024			Varia. Cinco días.	Varia. 1 de enero.
31,49 ^USD	+4,69 %		+5,46 %	-6,67 %

08/05	PACIRA BIOSCIENCES, INC. : El Needham & Co. continua con su recomendación de compra	ZM
07/05	Transcript : Pacira BioSciences, Inc., Q1 2024 Earnings Call, May 07, 2024

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

PACIRA BIOSCIENCES, INC. ANNOUNCES PRICING OF $250.0 MILLION AGGREGATE PRINCIPAL AMOUNT OF 2.125% CONVERTIBLE SENIOR NOTES DUE 2029	13/05
Pacira BioSciences Prices $250 Million Convertible Senior Notes Offering	10/05
Pacira BioSciences, Inc. Announces Pricing of $250.0 Million Aggregate Principal Amount of 2.125% Convertible Senior Notes due 2029	10/05
Pacira BioSciences, Inc. Announces Pricing of $250.0 Million Aggregate Principal Amount of 2.125% Convertible Senior Notes due 2029	10/05
Pacira BioSciences, Inc. Announces Proposed Offering of $250.0 Million Aggregate Principal Amount of Convertible Senior Notes	08/05
Pacira BioSciences, Inc. Announces Proposed Offering of $250.0 Million Aggregate Principal Amount of Convertible Senior Notes	08/05
Pacira BioSciences : 1Q 2024 Earnings Presentation	07/05
Pacira: Q1 Earnings Snapshot	07/05
Pacira BioSciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	07/05
Earnings Flash (PCRX) PACIRA BIOSCIENCES Reports Q1 Revenue $167.1M, vs. Street Est of $165.7M	07/05
Pacira BioSciences, Inc. announces an Equity Buyback for $150 million worth of its shares.	07/05
Pacira BioSciences Reports First Quarter 2024 Financial Results and Announces $150 Million Share Repurchase program	07/05
Pacira Biosciences, Inc. Reiterates Earnings Guidance for the Full Year 2024	07/05
Pacira BioSciences to Participate in Fireside Chat at the 2024 RBC Capital Markets Global Healthcare Conference	07/05
Pacira BioSciences, Inc. authorizes a Buyback Plan.	07/05
Pacira to Report First Quarter 2024 Financial Results on Tuesday May 7, 2024	30/04
Pacira BioSciences to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference	02/04
Beyond the Pill: Athletes Champion PEMF and Non-Opioid Solutions for Pain Management (ENDV)	20/03
Pacira BioSciences Says US FDA Granted Knee Osteoarthritis Therapy Candidate RMAT Designation	13/03
Pacira's PCRX-201 Gets FDA RMAT Designation in Knee Osteoarthritis	13/03

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Pacira BioSciences, Inc.

Acciones

PCRX

US6951271005

Otros idiomas

Filtros